Poland· PL-100354781
Zerbaxa
A ceftolozan und beta-lactamase-inhibitor product containing ceftolozanum + tazobactamum, registered in Poland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Ceftolozan und beta-lactamase-inhibitor is registered in 11 of 19 countries.
Countries holding a registration under ATC J01DI54 (ceftolozan und beta-lactamase-inhibitor), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Ceftolozan und beta-lactamase-inhibitor · ATC J01DI54
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Ceftolozanum + Tazobactamum
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Poland (PL)
- ATC code
- J01DI54
- ATC class
- Ceftolozan und Beta-Lactamase-Inhibitor
- Defined daily dose
- 3 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05901549324938
- gtin00191778013467
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ceftolozan und beta-lactamase-inhibitor in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaZERBAXAMerck Sharp & Dohme B.V., Haarlem
- CanadaZERBAXAMERCK CANADA INC
- SwitzerlandZerbaxa 1.5 g, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungMSD Merck Sharp & Dohme AG
- SpainZERBAXA 1 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FinlandZerbaxaMerck Sharp & Dohme B.V.
- FranceZERBAXA 1 g/0,5 g, poudre pour solution à diluer pour perfusionMERCK SHARP & DOHME (PAYS-BAS)
- United KingdomZerbaxa 1g/0.5g powder for concentrate for solution for infusion vialsMerck Sharp & Dohme (UK) Ltd
- IrelandZerbaxa 1 g/0.5 g powder for concentrate for solution for infusionMerck Sharp & Dohme BV,
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zerbaxa
- Liechtenstein · Zerbaxa
- Norway · Zerbaxa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b58aa49c-4ce7-428b-8b05-7492d7160388 GET /v1/drugs/b58aa49c-4ce7-428b-8b05-7492d7160388?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania koncentratu roztworu do infuzji",
"source": "urpl",
"strength": "1 g + 0,5 g",
"packaging": "05901549324938 ¦ Rp ¦ EU/1/15/1032/001 ¦ 111162\n10 fiol. proszku\n00191778013467 ¦ Rp ¦ Skasowane ¦ EU/1/15/1032/001 ¦ 127238\n10 fiol. proszku",
"substance": "Ceftolozanum 1 g + Tazobactamum 0.5 g",
"common_name": "Ceftolozanum + Tazobactamum",
"pl_product_id": "100354781",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about ceftolozan und beta-lactamase-inhibitor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.